Bristol-Myers Squibb Company
Every calculator, already run for BMY
Open the full toolkit →You have the numbers on BMY. Get the argument.
A written report on which of these readings actually decide the outcome for Bristol-Myers Squibb Company, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
28 analysts covering BMYAnalyst Price Target Disagreement for Bristol-Myers Squibb Company
Wall Street's bull case implies +34% from the current price; the bear case implies -35%. A 69% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for BMY
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of sym…
BMY — frequently asked
Is BMY a buy right now?
Wall Street's consensus rating on Bristol-Myers Squibb Company is Buy across 28 analysts, with a mean price target of $66.71 (+9% vs. the current $61.15). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is BMY overvalued?
BMY trades at 13.5x trailing earnings, against a DCF fair value of $154 per share. The current price implies -5% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is BMY's next earnings date?
Bristol-Myers Squibb Company is next scheduled to report earnings around Oct 29, 2026. A full BMY research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Bristol-Myers Squibb Company?
Analysts covering Bristol-Myers Squibb Company (BMY) range from a bear-case target of $40.00 to a bull-case high of $82.00, with a mean consensus target of $66.71 across 24 analysts. The spread of $42.00 (69% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Bristol-Myers Squibb Company against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Bristol-Myers Squibb Company
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full BMY research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Bristol-Myers Squibb Company, in minutes. 3 free reports included with every account — no credit card required.